What We're Reading: Page 377
Industry reads hand-picked by our editors
Mar 13, 2015
Mar 12, 2015
-
Bloomberg
23andMe to expand from genetic testing to new drug development
-
The Street
Acadia CEO to retire as Parkinson's drug is delayed again
-
FiercePharma
Teva probably won't buy Mylan—but should it?
-
Reuters
CVS: Biosimilars could cut prices in half
-
Medical Marketing & Media
Open Payments glitches inhibit pharma, device maker submissions
Mar 11, 2015
-
Wall Street Journal
Rx spending soared 12% last year, driven largely by hep C meds
-
Bloomberg
A post-plastics Bayer wants to net $27B per year in healthcare sales
-
The Guardian
For AstraZeneca CEO, fending off Pfizer takeover worth 5% pay bump
-
Reuters
Merck's Keytruda first approval under UK early access program
-
CBC
License to deceive: CBC gets Health Canada to endorse sham drug in investigation
Mar 10, 2015
-
Economic Times
India set to mandate side effect reporting to regulators
-
RAPS Regulatory Focus
FDA maps out generic approvals for 38 drugs, including Kalydeco
-
Bloomberg
How much will scientists use Apple's ResearchKit?
-
FiercePharma
Opdivo's survival benefit may have led to its rapid lung cancer approval
-
WSJ Pharmalot
A German agency's recommendation for determining drug cost-effectiveness
Mar 09, 2015
-
Bloomberg
Wall Street shrugging off high costs of new cancer treatments
-
The Telegraph
What's in store for Glaxo's new chairman?
-
In-Pharmatechnologist
Hospira's recall woes not over yet
-
Contract Pharma
Isis Pharma bags Biogen milestone
-
Indianapolis Business Journal
Lilly hopes NASCAR driver sponsorship will boost diabetes sales
Mar 06, 2015
-
FDA
FDA launches first drug-shortages mobile app
-
AbbVie beats out J&J, will buy Pharmacyclics for $21B to boost cancer pipeline
-
-
-
AstraZeneca to spin off antibiotics R&D for $40 million
-
BMS' Opdivo wins lung cancer indication more than 3 months before PDUFA date
-
Genentech denies knowledge of distribution-related problems
-
-
-
Akorn latest to reject use of its drugs for lethal injection
Mar 05, 2015
-
Could Sangamo's gene therapy 'cure' HIV?
-
-
-
The post-acquisition cuts begin: Valeant lays off 77 Dendreon employees
-
-
SEC to pharma: Don't get cute with disclosing FDA dealings to investors
-
-
BI files its Pradaxa 'antidote' in North America, EU
-
FDA clamps down on testosterone labeling rules
-
Orexigen shoots itself in foot with early disclosure of positive Contrave heart data
Previous
